MPM Capital secures $400M treasure chest for early biotechs

Drugs and money
The VC has previously founded and invested in Harpoon and Potenza. (Getty/LIgorko)

Life science VC MPM Capital is looking to boost funding for a select series of early-stage biotechs with a new $400 million fund.

This cash injection comes from its seventh venture fund, known as BioVentures 2018 (aka BV2018), and sits alongside its two cancer-only funds, which all together brings its VC cash budget to a cool $1 billion.

With BV2018, MPM says it will continue to “create and invest in innovative companies developing breakthrough therapies to treat severe unmet medical needs.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Specifically, it will focus on earlier science coming out of biotechs working in immunology and neuroscience, as well as emerging modalities of cell, gene and nucleic acid therapies.

RELATED: Surface’s Biniszkiewicz, Chappel join MPM Capital as executive partners

“We’re grateful for our investors’ support of BV2018, which will allow us to continue to pursue our proven company-building strategy with the goal of improving healthcare outcomes while creating value for our investors,” said Ansbert Gadicke, M.D., Ph.D., co-founder and managing director of MPM.

“The opportunity to drive innovation in drug development is more attainable than ever before. We believe this is particularly true in oncology where MPM has 29 oncology portfolio investments and approximately $1 billion of capital dedicated to developing novel cancer therapies.”

The alumni of MPM’s approach include freshly IPO’d Harpoon Therapeutics and TCR2 Therapeutics, as well as Mitobridge and Potenza Therapeutics, both of which were recently bought out by Astellas.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.